A Study of IBI3031 in Participants With Thyroid Eye Disease
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Thyroid Eye Disease
In brief
This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.
Key facts
- Study ID
- NCT07622368
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
- People needed
- 66
- Starts
- 2026-06-30
- Expected to finish
- 2027-12-28
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- the First Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.